Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$832.9MCash on Hand
CF+ Cash Runway
Follow QGEN by emailGet an email when QGEN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about QGEN, unsubscribe in one click. Privacy
📣 What QGEN Says Is Next
in 2028 · “We expect to adopt prospectively beginning with our interim reporting in 2028.”
Company press release, Nov 6, 2026 · SEC filing
in 2027 · “We are currently evaluating the impact of ASU 2025-09 and anticipate adopting prospectively at the effective date with our interim reporting in 2027.”
Company press release, Nov 6, 2026 · SEC filing
in 2026 · “New QIAcuity gene expression assays and a high-multiplex kit enabling analysis of up to 12 RNA targets in a single reaction are being launched in 2026.”
Company press release, Aug 7, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 6, 2026 ·
Earnings QIAGEN reported Q3 2026 net sales of $548 million, up 3%, with diluted EPS of $0.51 and adjusted diluted EPS of $0.65. It suspended 2026 guidance due to the pending all-cash takeover by EQT Private Equity at €46.50 per share. Form 6-K · SEC filing · Press release
Nov 6, 2026 ·
Earnings QIAGEN reported Q3 2026 net sales of $547,869 thousand, up from $532,583 thousand a year earlier, and net income of $105,659 thousand versus $130,043 thousand. Nine-month net income was $277,103 thousand. Cash and equivalents stood at $805,132 thousand at September 30, 2026. Form 6-K · SEC filing · Press release
Oct 23, 2026 ·
Deal QIAGEN and Crown NL Bidco B.V. agreed to a tender offer for all outstanding ordinary shares at €46.50 per share in cash, under a Business Combination Agreement dated October 21, 2026. Shareholder approval resolutions are contemplated at an extraordinary general meeting. Form 6-K · SEC filing · Press release
Sep 9, 2026 ·
Leadership QIAGEN appointed Jonathan M. Pratt as CEO effective September 1, 2026, succeeding Thierry Bernard, who also stepped down from the Managing Board. QIAGEN reaffirmed its 2026 outlook and continues its strategic review. Pratt will be proposed as Managing Director at a Q4 2026 meeting. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · N/A · Active Trial · Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR Registry primary completion date, not a results date
Dec 2027 · Phase 2 · Recruiting · A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease Registry primary completion date, not a results date
Sep 2028 · Phase 3 · Recruiting · A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma Registry primary completion date, not a results date
Oct 2030 · N/A · Recruiting · DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit Registry primary completion date, not a results date
May 2026 · N/A · Active Trial · Clinical Performance of QIAstat-Dx® Meningitis/Encephalitis (ME) Panel Plus Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
QGEN holds $832.9M in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Share count 216,920,735 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full QGEN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for QGEN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.